関: fursultiamin、fursultiamine hydrochloride

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/09/22 00:03:28」(JST)

wiki en

Fursultiamine (INN; Adventan, Alinamin-F, Benlipoid, Bevitol Lipophil, Judolor), also known as thiamine tetrahydrofurfuryl disulfide (TTFD), is a disulfide derivative of thiamine, or an allithiamine.^[1] It was synthesized in Japan in the 1960s for the purpose of developing forms of thiamine with improved lipophilicity for treating vitamin B₁ deficiency (i.e., beriberi),^[1]^[2] and was subsequently commercialized not only in Japan but also in Spain, Austria, Germany, and the United States.^[3] As a vitamin, it is available over-the-counter as well.^[4]

In addition to its clinical indication of avitaminosis, fursultiamine has been studied in clinical trials for Alzheimer's disease and autistic spectrum disorders with positive but modest benefits.^[5]^[6] It has also been investigated in improving energy metabolism during exercise and reducing exercise-induced fatigue with conflicting results.^[4]^[7]^[8]^[9]

Available Brands: Privitamix softgel (India)

References

^ ^a ^b Lonsdale D (September 2004). "Thiamine tetrahydrofurfuryl disulfide: a little known therapeutic agent". Medical Science Monitor : International Medical Journal of Experimental and Clinical Research 10 (9): RA199–203. PMID 15328496.
^ Miura S (July 1965). "[The uptake and the distribution of thiamine propyl disulfide-35S by the rabbit's eye tissue]". Nippon Ganka Gakkai Zasshi (in Japanese) 69 (7): 792–807, discussion 807–8. PMID 5006719.
^ Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. p. 1932. ISBN 3-88763-075-0.
^ ^a ^b Nozaki S, Mizuma H, Tanaka M et al. (December 2009). "Thiamine tetrahydrofurfuryl disulfide improves energy metabolism and physical performance during physical-fatigue loading in rats". Nutrition Research (New York, N.Y.) 29 (12): 867–72. doi:10.1016/j.nutres.2009.10.007. PMID 19963160.
^ Mimori Y, Katsuoka H, Nakamura S (March 1996). "Thiamine therapy in Alzheimer's disease". Metabolic Brain Disease 11 (1): 89–94. doi:10.1007/BF02080934. PMID 8815393.
^ Lonsdale D, Shamberger RJ, Audhya T (August 2002). "Treatment of autism spectrum children with thiamine tetrahydrofurfuryl disulfide: a pilot study". Neuro Endocrinology Letters 23 (4): 303–8. PMID 12195231.
^ Suzuki M, Itokawa Y (March 1996). "Effects of thiamine supplementation on exercise-induced fatigue". Metabolic Brain Disease 11 (1): 95–106. doi:10.1007/bf02080935. PMID 8815395.
^ Webster MJ, Scheett TP, Doyle MR, Branz M (1997). "The effect of a thiamin derivative on exercise performance". European Journal of Applied Physiology and Occupational Physiology 75 (6): 520–4. doi:10.1007/s004210050198. PMID 9202948.
^ Masuda H, Matsumae H, Masuda T, Hatta H (2010). "A thiamin derivative inhibits oxidation of exogenous glucose at rest, but not during exercise". Journal of Nutritional Science and Vitaminology 56 (1): 9–12. doi:10.3177/jnsv.56.9. PMID 20354340.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 夜間の足痙攣 nocturnal leg cramps

English Journal

High-throughput screening of small molecules identifies hepcidin antagonists.

Fung E1, Sugianto P, Hsu J, Damoiseaux R, Ganz T, Nemeth E.
Molecular pharmacology.Mol Pharmacol.2013 Mar;83(3):681-90. doi: 10.1124/mol.112.083428. Epub 2013 Jan 4.
Anemia of inflammation (AI) is common in patients with infection, autoimmune diseases, cancer, and chronic kidney disease. Unless the underlying condition can be reversed, treatment options are limited to erythropoiesis-stimulating agents with or without intravenous iron therapy, modalities that are
PMID 23292796

The effect of thiamin tetrahydrofurfuryl disulfide on behavior of juvenile DBA/2J mice.

Hills JI1, Golub MS, Bettendorff L, Keen CL.
Neurotoxicology and teratology.Neurotoxicol Teratol.2012 Mar;34(2):242-52. doi: 10.1016/j.ntt.2011.07.006. Epub 2011 Jul 24.
Due to genetic defects or illness some individuals require higher amounts of thiamin than are typically provided by the diet. Lipid-soluble thiamin precursors can achieve high blood levels of thiamin and result in increased concentrations in the central nervous system. High intakes of thiamin have b
PMID 21816221

Comparison of the effects of pantethine and fursultiamine on plasma gastrointestinal peptide levels in healthy volunteers.

Suzuki Y1, Itoh H, Abe T, Nishimura F, Sato Y, Takeyama M.
Biological & pharmaceutical bulletin.Biol Pharm Bull.2011;34(10):1640-3.
Pantethine and fursultiamine have been evaluated for their clinical usefulness in the treatment and prevention of uncomplicated postoperative adhesive intestinal obstruction. In recent years, the actions of drugs used to treat gastrointestinal diseases have been elucidated pharmacologically from the
PMID 21963510

Japanese Journal

Comparison of the Effects of Pantethine and Fursultiamine on Plasma Gastrointestinal Peptide Levels in Healthy Volunteers

Suzuki Yosuke,Itoh Hiroki,Abe Tomohide,Nishimura Fumihiro,Sato Yuhki,Takeyama Masaharu
Biological & Pharmaceutical Bulletin 34(10), 1640-1643, 2011
… Pantethine and fursultiamine have been evaluated for their clinical usefulness in the treatment and prevention of uncomplicated postoperative adhesive intestinal obstruction. … We examined the effects of pantethine and fursultiamine on plasma levels of calcitonin gene-related peptide (CGRP)-, vasoactive intestinal polypeptide (VIP)-, motilin- and substance P (SP)-like immunoreactive substances (IS) in healthy subjects. …
NAID 130001086602

慢性副鼻腔炎における嗅覚障害 - 臨床的, 組織形態学的検討 -

江川雅彦
日本耳鼻咽喉科學會會報 98(5), 843-854, 1995-05-20
実験的副鼻腔炎家兎における嗅上皮と呼吸上皮の組織障害とその治癒過程をHE染色, SEM, 抗BrdU抗体染色にて観察した. その結果, 治癒遅延の過程における嗅上皮への炎症の波及と嗅上皮の細胞分裂能が呼吸上皮より劣ることなどが明らかとなった. これらの所見は副鼻腔炎で見られる嗅覚障害が呼吸性とともに嗅上皮性障害を示すことを示唆した. 一方, 慢性副鼻腔炎で嗅覚障害を認める患者におけるニオイ紙による …
NAID 10006824485

Related Pictures

★リンクテーブル★

リンク元	「フルスルチアミン」
拡張検索	「fursultiamine hydrochloride」
関連記事	「fursultiamin」

「フルスルチアミン」

Fursultiamine
Systematic (IUPAC) name
	N-[(4-amino-2-methylpyrimidin-5-yl)methyl]-N-{(1E)-4-hydroxy-1-methyl-2-[(tetrahydrofuran-2-ylmethyl)disulfanyl]but-1-en-1-yl}formamide
Clinical data
AHFS/Drugs.com	International Drug Names
Legal status	OTC;
Routes of; administration	Oral
Identifiers
CAS Registry Number	804-30-8
ATC code	None
PubChem	CID: 3002119
DrugBank	DB08966
ChemSpider	2273321
UNII	05J61265PX
Chemical data
Formula	C17H26N4O3S2
Molecular mass	398.54 g/mol
	SMILES O=CN(\C(=C(\SSCC1OCCC1)CCO)C)Cc2cnc(nc2N)C ;